BASEL, Switzerland, Feb. 9 /CNW Telbec/ - Neuro-Biotech Corp.
(PINKSHEET: MRES) (OTCQB: MRES) is pleased to announce the signing of
its second License Agreement with Bato Investments, a company based out
of Tel-Aviv, Israel.
This Agreement provides for a minimum yearly order of 500,000 units over
a period of 10 years. Both parties have agreed on an initial price of
US$ 55.00 per unit, based on the price of the recently negotiated
agreement with Credo-TM, a Company based out of Russia. Each agreement
is estimated to bring in a gross profit of US$ 26,750,000 annually, for
a period of ten years. Negotiations are still ongoing with India,
Pakistan, Spain and Egypt. The terms of these agreements are projected
to be within the same range as the previous ones.
With the signing of this Agreement and ongoing negotiations,
Neuro-Biotech strengthens the implementation of its Licensees network
throughout the world, allowing the Company to begin the next phase of
its development plan: the creation of its own "Technological Showcase"
in order to support the training of technicians as well as the
development of new products and avoid any type of road show.
For more information on Neuro-Biotech Corp or to contact a company
representative, please visit: www.neuro-biotechcorp.com
FORWARD LOOKING STATEMENTS
This release contains statements that are made pursuant to the Safe
Harbor Provisions of the Private Securities Litigation Act of 1995.
Certain statements in this press release may contain words such as
"anticipates," "believes," "could," "expects," "intends," "may,"
"projects," "targets" and other similar language that is considered
forward-looking statements. These forward-looking statements are
subject to certain risks and uncertainties and persons reading this
release are cautioned that such statements are only predictions, and
that the Company's actual future results or performance may be
materially different. The Company disclaims any intention or obligation
to update or revise forward-looking information, whether as a result of
new information, future events, or otherwise, could cause the company's
actual results to differ materially from those indicated in any
SOURCE Neuro-Biotech Corp.
For further information:
Dr. Claude Poulin
41 61 500 05 16